

Committee Report 2024

ESO Public Relations and Social Media Committee

Inna Lutsenko

20.01.25

Report of the ESO Committees - Summary

Public Relations and Social Media Committee current members

- **Inna Lutsenko, Austria (Chair)**
- Ahmed Guncan, Turkey
- Christian Böhme, Austria
- Francesco Arba, Italy
- Thomas Meinel, Switzerland



Inna Lutsenko, Dr.med.univ. @inna_lutsenko · May 16, 2024



Do you know these people?

It's a Social Media and public relations team hardly working and writing for you the sessions reports - check [@ESOstroke](#) Blogs to read the latest research! [@TotoMynell](#) [@chris7ianb](#), Zdravka Polakovic and me at [#ESOC2024](#)



Report of the ESO Public Relations Committee

Sessions covered at the ESOC 2023 at the Blog Post

<u>Session ID SS16: Is Inflammation the Next Frontier in Stroke Prevention?</u>	Christian Boehme
<u>Session ID SS3: Preventive Measurements in ICH: From Aneurysms and Beyond (joint with EAN)</u>	Inna Lutsenko, Ahmed Gunkan
<u>Session ID SS12: Artificial Intelligence and Digital Health Technologies</u>	Thomas Meinel
<u>Session ID SS4: Back to Basics: Non-Contrast CT in Acute Stroke Care</u>	Francesco Arba
<u>Session ID SS4: Ischemic Stroke in Cancer</u>	Christian Boehme
<u>Session ID SC10: Hyperacute Management</u>	Christian Boehme
<u>Session ID SC4: Cardioembolism and Heart-Brain Interactions</u>	Christian Boehme
<u>Session ID SC17: Secondary Prevention</u>	Francesco Arba
<u>Session ID SC15: Thrombolysis</u>	Christian Boehme

Report of the ESO Public Relations Committee

Sessions covered at the ESOC 2024 at the Blog Post

<u>Session ID SS16: Is Inflammation the Next Frontier in Stroke Prevention?</u>	Christian Boehme
<u>Session ID SC13: Large Clinical Trials Session</u>	Christian Boehme
<u>Session ID SC18: Thrombolysis for Acute Ischemic Stroke – Exploring the Grey</u>	Christian Boehme
<u>Session ID TC6: Management of Stroke Complications (Acute & Subacute)</u>	Inna Lutsenko
<u>Session ID SS16: Is Inflammation the Next Frontier in Stroke Prevention?</u>	Christian Boehme

Report of the ESO Public Relations Committee


ESO Blogs-Boosts devoted to the ESOC Anniversary

Inna Lutsenko	LOOKING BACK AT 2017: PICASSO TRIAL – THE ROLE OF CILOSTAZOL AND PROBUCOL IN PREVENTION OF CEREBROVASCULAR EVENTS
Inna Lutsenko	INTERVIEW WITH DR. AHMED KHALIL
Inna Lutsenko	<u>Interview with Dr. Sabrina Eltringham</u>

Interview with Dr. Ahmed Khalil

Stroke Researcher and Medical Resident
Center for Stroke Research Berlin, Charité Universitätsmedizin, Berlin
Twitter: @AhmedAAKhalil

Interviewed by Dr. Inna Lutsenko
ESO Social Media and PR Committee
Neurologist, Hietzing Hospital, Vienna, Austria
Twitter: @inna_lutsenko



LOOKING BACK AT 2017: PICASSO TRIAL – THE ROLE OF CILOSTAZOL AND PROBUCOL IN PREVENTION OF CEREBROVASCULAR EVENTS

22/03/2024 / in ESOC / by Carine Legio

Author:

Dr. Inna Lutsenko, ESO Social Media and PR Committee
Department of Neurology, Hietzing Hospital, Vienna, Austria
Twitter: @inna_lutsenko



By Dr. Inna Lutsenko



ESO Blogs by ESO SM and PR Committee

<p><u>Decoding Atherosclerotic Plaque Inflammation: Insights from Experimental Studies, Part One</u></p>	<p>Inna Lutsenko</p>
<p><u>Management Options for Atrial Fibrillation Patients Experiencing Stroke Despite Anticoagulation</u></p>	<p>Thomas Meinel</p>



Tweets shared during ESO Webinars und at ESOC with hashtags


2.000- 12.000 views

 **Inna Lutsenko, Dr.med.univ.** @inna_lutsenko · May 17, 2024
Mira Katan at @ESOstroke #ESOC2024

NOT #ESUS anymore:

Heart source for an #embolic #stroke in absence of AF:

- ➔ left atrial fibrosis
- ➔ left atrial endothelial dysfunction
- ➔ left atrial chamber dilatation
- ➔ reduced ejection fraction



Identifying sources of cardiac embolism ?

- Not detected but underlying atrial fibrillation (AF)
- Atrial dysfunction even in absence of AF
 - Left atrial fibrosis
 - Left atrial endothelial dysfunction
 - Left atrial chamber dilatation
 - Impaired contractility with reduced left atrial ejection fraction
 - Parasympathetic dysfunction (shortening of refractoriness in the atria)
- Silent ventricular Dysfunction

COVERT CARDIO-EMBOLIC SOURCE

- Small artery disease TOAST 3
- Large artery atherosclerotic stroke TOAST 1
- Cryptogenic stroke TOAST 5
- Cardioembolic Stroke-TOAST 2
- Other determined etiology TOAST 4

🗨️ 9 ❤️ 36 📊 1.3K 📌 📤

 **Inna Lutsenko, Dr.med.univ.** @inna_lutsenko · May 17, 2024
#SELECT-2 analysis showed that

no significant benefit of #endovascular therapy was observed in patients presenting with increasing volumes of severe #hypodensity on pre-treatment CT-imaging

Vignan Yogendrakumar at #ESOC2024 @ESOstroke



STUDY OBJECTIVES

- Investigate the association between CT-hypodensities volume and EVT outcomes in patients presenting with and without hemorrhagic transformation (HT) in the study population.
- Identify clinically relevant volumes of severe CT-hypodensity that may be associated with reduced EVT treatment effect and increased risk of hemorrhagic transformation.

METHODS

Contralateral Thalamic Densities

Defining Severe Hypodensity

- ROI of contralateral thalamus drawn for each patient
- 0.5th percentile pooled across all patients
- Median Value selected as primary HU threshold of interest

Volume ≤ 26ml of Severe Hypodensity (n=221)

	EVT + MM (n=129)	MM (n=92)	Effect Size: aOR (95%CI)	EVT + MM (n=45)	MM (n=6)	Effect Size: aOR (95%CI)	P-value
sICH	0 (0%)	1 (1%)	NA	0 (0%)	1 (2%)	NA	NA
Death within 90 days	40 (33%)	40 (40%)	0.89 (0.51-1.53)	23 (51%)	25 (42%)	1.44 (0.57-3.62)	0.14
Discomprossive Hemorrhage	14 (12%)	14 (14%)	0.74 (0.31-1.75)	13 (29%)	9 (16%)	3.45 (1.05-10.88)	0.04

Volume > 26 ml of Severe Hypodensity (n=40)

	EVT + MM (n=20)	MM (n=20)	Effect Size: aOR (95%CI)
sICH	0 (0%)	0 (0%)	NA
Death within 90 days	10 (50%)	10 (50%)	0.85 (0.28-2.62)
Discomprossive Hemorrhage	5 (25%)	5 (25%)	0.85 (0.28-2.62)

SUMMARY

- Compared to medical management, no significant benefit of endovascular therapy was observed in patients presenting with increasing volumes of severe hypodensity on pre-treatment CT-imaging.
- Substantial volumes of severe hypodensity were associated with increased median mRS and an increased need for hemorrhagic transformation therapy.
- Algorithm used to evaluate tissue hypodensities are novel - requires external validation.
- Proof of concept that highlights the importance of the gradient of tissue ratio within the brain.

🗨️ 9 ❤️ 36 📊 1.3K 📌 📤

Summary of ESO SM and PR activities:

- Multiplied and advertised the ESO activities on Twitter and LinkedIn
- Educational twitter threads based on ESO Guidelines and webinars (Lutsenko)
- visibility of #ESOC2024 through Twitter (Lutsenko, Meinel)
- ESOC 2024 sessions covered in Blogs
- Tweets covering the educational webinars
- ESO Blogposts (Lutsenko, Meinel)
- Engaging with followers, responding to comments, and fostering a sense of community



Inna Lutsenko, Dr.med.univ. @inna_lutsenko · Jan 24, 2024



Salvatore Rudilosso is now talking about the case study about a patient with multiple cover infarctions at [#ESO Covert cerebral infarctions webinar](#)

🩸 SWI Sequence at MRI shows cortical micro bleeds

⚡ At DWI : right lenticular nucleus lesion

[@ESOstroke](#)

